Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [HEALTH]
2 clusters · 7 sources · 30 days · First seen · Last updated
Novo Nordisk CagriSema clinical trial results
Overview
Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity.
Initial results from the Phase 3 REIMAGINE 5 study involving adults with type 2 diabetes showed that patients lost an average of 12.4% of their body weight over 60 weeks. This outperformed the 9.1% weight loss observed in patients treated with 5 mg of tirzepatide, though researchers noted it did not necessarily exceed the results of higher doses of Mounjaro.
Subsequent post-trial analysis from the Phase 3 REDEFINE 1 trial, which included approximately 2,300 women, reported an average body weight reduction of 25% for those receiving a 2.4 mg combination of the drugs. Further analysis by reproductive stage indicated weight loss estimates of 26.7% for premenopausal women, 24.8% for perimenopausal women, and 23.1% for postmenopausal women. The medication also demonstrated links to reduced waist circumference across all studied groups.
Entities
Novo Nordisk · CagriSema · The Menopause Society · REDEFINE 1 · Eli Lilly
Timeline
-
[HEALTH] 5 sourcesNovo Nordisk experimental drug CagriSema shows 25% weight loss in women
Novo Nordisk's experimental drug CagriSema achieved an average 25% weight loss in women during a Phase 3 trial analysis, showing efficacy across different menopause stages.
-
[HEALTH] 2 sourcesNovo Nordisk CagriSema shows higher weight loss than Mounjaro in Phase 3 study
Novo Nordisk's experimental drug CagriSema showed higher average weight loss than a 5 mg dose of Mounjaro in a Phase 3 study, while the rise of such drugs increases demand for skin-tightening plastic surgery.
Sources
diariodesalud.com.do · foreignpolicyjournal.com · infomoney.com.br · latercera.com · oglobo.globo.com · pharmacytimes.com · tokenpost.com